Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy

Highlights • 9.9% of patients exceeding 200 μg/dL ammonia during VPA-based therapy. • 14.9% of patients exceeding 170 μg/dL ammonia during VPA-based therapy. • GLUL rs10797771 polymorphism was a risk factor for exceeding 200 μg/dL ammonia level. • Phenytoin coadministration was a risk factor for exc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Seizure (London, England) England), 2015-12, Vol.33, p.76-80
Hauptverfasser:	Inoue, Kazuyuki, Takahashi, Toshiki, Yamamoto, Yoshiaki, Suzuki, Eri, Takahashi, Yukitoshi, Imai, Katsumi, Inoue, Yushi, Hirai, Keita, Tsuji, Daiki, Itoh, Kunihiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Ammonia - blood Anticonvulsants - adverse effects Child Child, Preschool Epilepsy Epilepsy - drug therapy Epilepsy - genetics Female Genotype Glutamate-Ammonia Ligase - genetics Glutamine synthetase Humans Hyperammonemia Hyperammonemia - chemically induced Hyperammonemia - genetics Infant Infant, Newborn Logistic Models Male Neurology Phenytoin - adverse effects Polymorphism Polymorphism, Genetic - genetics Sex Factors Valproic acid Valproic Acid - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • 9.9% of patients exceeding 200 μg/dL ammonia during VPA-based therapy. • 14.9% of patients exceeding 170 μg/dL ammonia during VPA-based therapy. • GLUL rs10797771 polymorphism was a risk factor for exceeding 200 μg/dL ammonia level. • Phenytoin coadministration was a risk factor for exceeding 200 μg/dL ammonia level. • Female gender was a risk factor for exceeding 170 μg/dL ammonia level.
ISSN:	1059-1311 1532-2688
DOI:	10.1016/j.seizure.2015.10.015